awmsg logo



selexipag (Uptravi®)


Reference No. 700

Publication date:
12/06/2018


Appraisal information

selexipag (Uptravi®) 200 microgram film-coated tablet
selexipag (Uptravi®) 400 microgram film-coated tablet
selexipag (Uptravi®) 600 microgram film-coated tablet
selexipag (Uptravi®) 800 microgram film-coated tablet
selexipag (Uptravi®) 1,000 microgram film-coated tablet
selexipag (Uptravi®) 1,200 microgram film-coated tablet
selexipag (Uptravi®) 1,400 microgram film-coated tablet
selexipag (Uptravi®) 1,600 microgram film-coated tablet


Company: Actelion Pharmaceuticals UK Ltd
BNF category: Cardiovascular system
NMG meeting date: 07/02/2018
AWMSG meeting date: 23/05/2018
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0918
Ratification by Welsh Government: 11/06/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Selexipag (Uptravi®) is recommended as an option for restricted use within NHS Wales. Selexipag (Uptravi®) is licensed for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Selexipag (Uptravi®) is recommended as an option for restricted use within NHS Wales as a triple combination therapy for the treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) III who are insufficiently controlled on dual therapy with an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. Selexipag (Uptravi®) is not recommended for use within NHS Wales outside of this sub-population. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download